In conclusion, this approach showed that selective elimination of CD26+ CML LSCs/progenitor cells can be obtained in vitro, which might allow in vivo reduction of side effects and attainment of treatment-free, long-lasting remission in CML patients. The gene discussed is DPP4; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.